Carlo Marchetti1,2,3, Jeremy Chojnacki4, Stefano Toldo1,2, Eleonora Mezzaroma1,2,5, Nicla Tranchida1,2, Scott W Rose1,2, Massimo Federici3, Benjamin W Van Tassell1,2,5, Shijun Zhang4, Antonio Abbate1,2. 1. VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA. 2. Victoria Johnson Research laboratories, Virginia Commonwealth University, Richmond, VA, USA. 3. Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. 4. Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA. 5. Department of Pharmacotherapy and Outcome Studies, Virginia Commonwealth University, Richmond, VA, USA.
Abstract
BACKGROUND: The formation of the NLRP3 inflammasome in the heart during acute myocardial infarction amplifies the inflammatory response and mediates further damage. Glyburide has NLRP3 inhibitory activity in vitro but requires very high doses in vivo, associated with hypoglycemia. The aim of this study was to measure the effects on the NLRP3 inflammasome of 16673-34-0, an intermediate substrate free of the cyclohexylurea moiety, involved in insulin release. METHODS AND RESULTS: We synthesized 16673-34-0 (5-chloro-2-methoxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide) that displayed no effect on glucose metabolism. HL-1 cardiomyocytes were treated with lipopolysaccharide and ATP to induce the formation of the NLRP3 inflammasome, measured as increased caspase-1 activity and cell death, and 16673-34-0 prevented such effects. 16673-34-0 was well tolerated with no effects on the glucose levels in vivo. Treatment with 16673-34-0 in a model of acute myocardial infarction because of ischemia and reperfusion significantly inhibited the activity of inflammasome (caspase-1) in the heart by 90% (P < 0.01) and reduced infarct size, measured at pathology (by >40%, P < 0.01) and with troponin I levels (by >70%, P < 0.01). CONCLUSIONS: The small molecule 16673-34-0, an intermediate substrate in the glyburide synthesis free of the cyclohexylurea moiety, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size after myocardial ischemia-reperfusion in the mouse, without affecting glucose metabolism.
BACKGROUND: The formation of the NLRP3 inflammasome in the heart during acute myocardial infarction amplifies the inflammatory response and mediates further damage. Glyburide has NLRP3 inhibitory activity in vitro but requires very high doses in vivo, associated with hypoglycemia. The aim of this study was to measure the effects on the NLRP3 inflammasome of 16673-34-0, an intermediate substrate free of the cyclohexylurea moiety, involved in insulin release. METHODS AND RESULTS: We synthesized 16673-34-0 (5-chloro-2-methoxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide) that displayed no effect on glucose metabolism. HL-1 cardiomyocytes were treated with lipopolysaccharide and ATP to induce the formation of the NLRP3 inflammasome, measured as increased caspase-1 activity and cell death, and 16673-34-0 prevented such effects. 16673-34-0 was well tolerated with no effects on the glucose levels in vivo. Treatment with 16673-34-0 in a model of acute myocardial infarction because of ischemia and reperfusion significantly inhibited the activity of inflammasome (caspase-1) in the heart by 90% (P < 0.01) and reduced infarct size, measured at pathology (by >40%, P < 0.01) and with troponin I levels (by >70%, P < 0.01). CONCLUSIONS: The small molecule 16673-34-0, an intermediate substrate in the glyburide synthesis free of the cyclohexylurea moiety, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size after myocardial ischemia-reperfusion in the mouse, without affecting glucose metabolism.
Authors: Antonio Abbate; Michael C Kontos; John D Grizzard; Giuseppe G L Biondi-Zoccai; Benjamin W Van Tassell; Roshanak Robati; Lenore M Roach; Ross A Arena; Charlotte S Roberts; Amit Varma; Christopher C Gelwix; Fadi N Salloum; Andrea Hastillo; Charles A Dinarello; George W Vetrovec Journal: Am J Cardiol Date: 2010-04-02 Impact factor: 2.778
Authors: W C Claycomb; N A Lanson; B S Stallworth; D B Egeland; J B Delcarpio; A Bahinski; N J Izzo Journal: Proc Natl Acad Sci U S A Date: 1998-03-17 Impact factor: 11.205
Authors: Eleonora Mezzaroma; Stefano Toldo; Daniela Farkas; Ignacio M Seropian; Benjamin W Van Tassell; Fadi N Salloum; Harsha R Kannan; Angela C Menna; Norbert F Voelkel; Antonio Abbate Journal: Proc Natl Acad Sci U S A Date: 2011-11-21 Impact factor: 11.205
Authors: Stefano Toldo; Ignacio M Seropian; Eleonora Mezzaroma; Benjamin W Van Tassell; Fadi N Salloum; Eli C Lewis; Norbert Voelkel; Charles A Dinarello; Antonio Abbate Journal: J Mol Cell Cardiol Date: 2011-05-12 Impact factor: 5.000
Authors: Mohamed Lamkanfi; James L Mueller; Alberto C Vitari; Shahram Misaghi; Anna Fedorova; Kurt Deshayes; Wyne P Lee; Hal M Hoffman; Vishva M Dixit Journal: J Cell Biol Date: 2009-10-05 Impact factor: 10.539
Authors: Darrell Wu; Pingping Ren; Yanqiu Zheng; Lin Zhang; Gaiping Xu; Wanmu Xie; Eric E Lloyd; Sui Zhang; Qianzi Zhang; John A Curci; Joseph S Coselli; Dianna M Milewicz; Ying H Shen; Scott A LeMaire Journal: Arterioscler Thromb Vasc Biol Date: 2017-02-02 Impact factor: 8.311
Authors: Coert J Zuurbier; Antonio Abbate; Hector A Cabrera-Fuentes; Michael V Cohen; Massimo Collino; Dominique P V De Kleijn; James M Downey; Pasquale Pagliaro; Klaus T Preissner; Masafumi Takahashi; Sean M Davidson Journal: Cardiovasc Res Date: 2019-06-01 Impact factor: 10.787
Authors: Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo Journal: Mol Med Date: 2014-06-12 Impact factor: 6.354
Authors: Carlo Marchetti; Stefano Toldo; Jeremy Chojnacki; Eleonora Mezzaroma; Kai Liu; Fadi N Salloum; Andrea Nordio; Salvatore Carbone; Adolfo Gabriele Mauro; Anindita Das; Ankit A Zalavadia; Matthew S Halquist; Massimo Federici; Benjamin W Van Tassell; Shijun Zhang; Antonio Abbate Journal: J Cardiovasc Pharmacol Date: 2015-07 Impact factor: 3.105